Linked Life Data

18605790

Source:http://linkedlifedata.com/resource/pubmed/id/18605790

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18605790rdf:typepubmed:Citationlld:pubmed
pubmed-article:18605790lifeskim:mentionsumls-concept:C0086541lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C0023280lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C0023276lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:18605790lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:18605790pubmed:issue3lld:pubmed
pubmed-article:18605790pubmed:dateCreated2008-7-8lld:pubmed
pubmed-article:18605790pubmed:abstractTextOld World cutaneous leishmaniasis is caused by infection with Leishmania major and Leishmania tropica. Pentamidine and related dications exhibit broad spectrum antiprotozoal activity. Based on the previously reported efficacy of these compounds against related organisms, 18 structural analogs of pentamidine were evaluated for in vitro antileishmanial activity, using pentamidine as the standard reference drug for comparison. Furan analogs and reversed amidine compounds were examined for activity against L. major and L. tropica promastigotes. The most active compounds against both Leishmania species were in the reversed amidine series. DB745 and DB746 exhibited the highest activity against L. major and DB745 was the most active compound against L. tropica. Both of these compounds exhibited 50% inhibitory concentrations (IC50) below 1 nM for L. major. Ten reversed amidines were also tested for their ability to inhibit growth in an axenic amastigote model. Nine of 10 reversed amidine analogs were active at concentrations below 1 nM. These results justify further study of dicationic compounds as potential new agents for treating cutaneous leishmaniasis.lld:pubmed
pubmed-article:18605790pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18605790pubmed:languageenglld:pubmed
pubmed-article:18605790pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18605790pubmed:citationSubsetIMlld:pubmed
pubmed-article:18605790pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18605790pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18605790pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18605790pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18605790pubmed:statusMEDLINElld:pubmed
pubmed-article:18605790pubmed:monthJunlld:pubmed
pubmed-article:18605790pubmed:issn0022-3395lld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:RosypalAlexa...lld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:KumarArvindAlld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:TidwellRichar...lld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:BoykinDavid...lld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:WerbovetzKarl...lld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:HallJames EJElld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:StephensChad...lld:pubmed
pubmed-article:18605790pubmed:authorpubmed-author:SalemManarMlld:pubmed
pubmed-article:18605790pubmed:issnTypePrintlld:pubmed
pubmed-article:18605790pubmed:volume94lld:pubmed
pubmed-article:18605790pubmed:ownerNLMlld:pubmed
pubmed-article:18605790pubmed:authorsCompleteYlld:pubmed
pubmed-article:18605790pubmed:pagination743-9lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:meshHeadingpubmed-meshheading:18605790...lld:pubmed
pubmed-article:18605790pubmed:year2008lld:pubmed
pubmed-article:18605790pubmed:articleTitleInhibition by Dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis.lld:pubmed
pubmed-article:18605790pubmed:affiliationSchool of Medicine, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.lld:pubmed
pubmed-article:18605790pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18605790pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18605790pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18605790lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18605790lld:pubmed